6. Rheum disease activity was stable with COVID vaccination. (RA, PsA, axSpA, SLE - total n = 597) 7/ LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0

Israel was early to COVID vaccinate on mass scale. How well did the vaccine work in their rheum dx pts? rheum pts n=686 (vs controls n = 121) - fewer w immunogencity, but not bad (86% vs 100%) - safety good - dx activity stable more details below ⬇️ LB0003 #EULAR2021 @RheumNow https://t.co/h2WT404mkF

Rituximab in PMR. Intriguing proof of concept (SB?) RCT (1:1, total n=47 (recent dx 38/relapsing 9)) 17w rapid PNL taper ritux 1g x1 21w: steroid-free remission: 48% v 21% PNL ≤5mg/d: 100% v 54% effect mainly from recent dx pts We do need options! POS0343 #EULAR2021 @RheumNow https://t.co/g6xJekY92O

Treat-to-target is the robust algorithm that dictates all modern RA treatment. What's the target? Ummmm We use it in everyone, right? (both doctors & pts say 66%) We at least use the principles sometimes, right? (86% of us) [holds up mirror to self] POS0305 #EULAR2021 @RheumNow https://t.co/A9MXHMYbag

On choosing an agent for MTX-IR RA: "(at the end of talk) My short answer could have been... there's no right or wrong. It's still one of the dilemmas we have in the treatment of RA: choosing the right drug for the right patient" - @DanielAletaha #EULAR2021 @RheumNow https://t.co/C45ey1SrA1

@KDAO2011 @UpToDate @TammyTilley @ACRheum @CreakyJoints @UnaMakris @DrDavidKarp @JointMD @ejdein1 @jeffsparks @Janetbirdope @uptoTate @RichardPAConway @MeralElRamahiMD @Yuz6Yusof @AurelieRheumo @Stiddyo @doctorRBC @RheumNow also, and I still remember this from the very first time I met him in person: "Do you know what the most important thing to remember is?" (nervous pause from me) "Have fun. You've gotta have fun!" I still live by this...

I write more about this for @RheumNow - it’s powerful to know that AI can accurately tell the difference between RA, PsA, and healthy controls on the basis of the bony surface at MCP 2: https://t.co/ChDfihnW4f @LkasDer @maier_ak @FAU_Germany OP0145 #EULAR2021 (ping @DrCMcMaster) https://t.co/Pl7yxYfEqr

• Artificial intelligence brings clarity to early bony changes in inflammatory ar…
• https://twitter.com/drdavidliew/status/1400725921208803333

#OP0223 US disease activity and damage score for PsA - ~300 patients from 19 centres - 6 components for disease activity score & 5 for damage -->~90% variability explained --> weighted score -->many sites to scan --> evaluation as BL pred. for MDA #EULAR2021 @RheumNow https://t.co/5kC6YDQi8D

#OP0219 Population based matched medical record database study in PsA vs. non PsA from Israel: -> no differences in mortality -> BL predictors of death -higher risk: higher age, male sex, prior hospitalisation, prior psoriasis, comorbidties -lower: csDMARDs #EULAR2021 #RheumNow

@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear. Head to head JAK-i vs. non-TNFi interesting Brilliant developing discussion number needed to harm vs. number needed to treat #EULAR2021 @RheumNow

Making decisions session at #EULAR2021 @DanielAletaha When designing for a superiority trial you cannot conclude on non-inferiority. Trials in JAK-i show more or less similar efficacy results to #TNFi Some JAK-i might work better for specific patient #pain #EULAR2021 @RheumNow https://t.co/Bo81nwBFbZ

#OP0220 EuroSpA 17 European registries 17452 bionaive PsA Patients 1999-2018: BL age, disease duration, disease activity decreased 99-18 - disease activity progressively decreased on treatment - At 6M REM rates higher in recent years, 24M REM rates similar #EULAR2021 @RheumNow https://t.co/gZ4tOpRLIf

OP0318 What to consider when tapering DMARDs RETRO – RA pat with DAS<2.6 for >=6months randomised to 3 strategies: remain – taper to 50% - taper then STOP HR for flare 3|4.3 for TAP|STOP Remission depth, disease duration and RF/ACPA as risks to consider #EULAR2021 @RheumNow https://t.co/SR4NDKKrGN

#POS0660 Integrated data analyses of the DARWIN, and FINCH studies (7 in total) on #filgotinib and #statin use: > Around 10% of 4057 RA patients used statins at baseline > Muscle related AE were rare with no clear relation to filgotinib #EULAR2021 @RheumNow

#POS0930 @XBaraliakos investigated baseline predictors differential treatment effect on ASAS20 response at week 12 of 473 ax-PsA using MAXIMISE trial data (#Secukinumab) -> Only nail dystrophy OR: 3 (150mg) OR: 5 (300mg) 🤔But why? #EULAR2021 @RheumNow https://t.co/srb6jGgBqe